Avidity Biosciences Inc’s recent filing unveils that its President and CEO Boyce Sarah unloaded Company’s shares for reported $0.62 million on Jan 07 ’26. In the deal valued at $72.23 per share,8,576 shares were sold. As a result of this transaction, Boyce Sarah now holds 283,394 shares worth roughly $20.53 million.
Then, Calderaro Charles III sold 3,727 shares, generating $269,201 in total proceeds. Upon selling the shares at $72.23, the Chief Technical Officer now owns 49,797 shares.
Before that, McCarthy Teresa sold 1,965 shares. Avidity Biosciences Inc shares valued at $141,932 were divested by the Chief Human Resources Officer at a price of $72.23 per share. As a result of the transaction, McCarthy Teresa now holds 116,867 shares, worth roughly $8.46 million.
Roth Capital initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on September 17, 2025; the price target was $62. Bernstein began covering RNA with “an Outperform” recommendation on June 24, 2025. Wolfe Research started covering the stock on June 17, 2025. It rated RNA as “an Outperform”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 0.11% to $72.43. Over the last five days, the stock has gained 0.25%. Avidity Biosciences Inc shares have risen nearly 145.86% since the year began. Nevertheless, the stocks have risen 0.42% over the past one year.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-12-31, dropping by 73782.0 shares to a total of 8.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 8.87 million shares. There was a decline of -0.84%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 11, 2025 when Raymond James began covering the stock and recommended ‘”a Strong buy”‘ rating along with a $65 price target.
